| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EVL |
| Uniprot No | Q9UI08 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-416aa |
| 氨基酸序列 | MSEQSICQAR ASVMVYDDTS KKWVPIKPGQ QGFSRINIYH NTASNTFRVV GVKLQDQQVV INYSIVKGLK YNQATPTFHQ WRDARQVYGL NFASKEEATT FSNAMLFALN IMNSQEGGPS SQRQVQNGPS PDEMDIQRRQ VMEQHQQQRQ ESLERRTSAT GPILPPGHPS SAASAPVSCS GPPPPPPPPV PPPPTGATPP PPPPLPAGGA QGSSHDESSM SGLAAAIAGA KLRRVQRPED ASGGSSPSGT SKSDANRASS GGGGGGLMEE MNKLLAKRRK AASQSDKPAE KKEDESQMED PSTSPSPGTR AASQPPNSSE AGRKPWERSN SVEKPVSSIL SRTPSVAKSP EAKSPLQSQP HSRMKPAGSV NDMALDAFDL DRMKQEILEE VVRELHKVKE EIIDAIRQEL SGISTT |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EVL重组蛋白的3篇参考文献示例(内容基于文献主题模拟，建议通过学术数据库核对原文)：
1. **标题**：*"Recombinant EVL Protein Regulates Actin Cytoskeleton Dynamics in Migrating Cells"*
**作者**：Chen L, et al.
**摘要**：该研究通过在大肠杆菌中表达并纯化重组EVL蛋白，分析了其对肌动蛋白组装的影响。实验表明，EVL通过抑制肌动蛋白纤维解聚促进细胞定向迁移，为肿瘤转移机制提供了新见解。
2. **标题**：*"Structural and Functional Analysis of the EVL C-Terminal Domain"*
**作者**：Saito K, et al.
**摘要**：利用重组EVL蛋白的C端结构域进行结晶和体外结合实验，揭示了其与Arp2/3复合物的相互作用模式，阐明了EVL在细胞骨架重塑中的分子机制。
3. **标题**：*"Development of a High-Yield EVL Recombinant Expression System in Mammalian Cells"*
**作者**：Wang Y, et al.
**摘要**：优化了哺乳动物细胞中EVL重组蛋白的表达条件，实现了高产量和正确翻译后修饰，为基于EVL的功能性药物筛选平台奠定了基础。
建议通过PubMed或Google Scholar以关键词“EVL recombinant protein”或“Ena/VASP EVL”检索最新文献获取具体信息。
**Background of EVL Recombinant Protein**
The Ena/VASP-like protein (EVL), a member of the Ena/VASP family (Enabled/vasodilator-stimulated phosphoprotein), plays a critical role in regulating cytoskeletal dynamics, particularly actin filament assembly and cell motility. EVL is involved in cellular processes such as cell migration, adhesion, and morphogenesis by interacting with actin-binding proteins and modulating actin polymerization. Its functional domains, including the Ena/VASP homology 1 (EVH1) domain, which mediates protein-protein interactions, and the EVH2 domain, responsible for actin binding, enable EVL to coordinate signaling pathways that influence cell shape and movement.
Recombinant EVL protein is engineered through molecular cloning techniques, typically expressed in *E. coli* or mammalian cell systems, to ensure high purity and bioactivity. This recombinant form retains the structural and functional properties of native EVL, making it a valuable tool for studying actin-driven processes *in vitro* or in cell-based assays. Researchers utilize EVL recombinant protein to investigate its role in diseases linked to cytoskeletal dysregulation, such as cancer metastasis, neuronal development disorders, and immune cell dysfunction.
EVL’s interaction with key signaling molecules, including Rac/Rho GTPases and focal adhesion kinases, highlights its importance in pathways governing cell polarity and directional migration. Studies have also explored its tumor-suppressive potential in certain cancers, where EVL downregulation correlates with increased invasiveness. Additionally, EVL recombinant protein aids in drug discovery, serving as a target for compounds aimed at modulating cytoskeletal dynamics in pathological conditions.
Overall, EVL recombinant protein bridges fundamental research and therapeutic development, offering insights into cell biology mechanisms and potential clinical applications. Its study continues to uncover novel roles in health and disease, emphasizing its significance in both basic and translational sciences.
×
